Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Kleiweg 500, 3045 PM Rotterdam, the Netherlands.
Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Kleiweg 500, 3045 PM Rotterdam, the Netherlands; Department of Cardiology, Erasmus MC, 's Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands.
Clin Chim Acta. 2018 Dec;487:117-125. doi: 10.1016/j.cca.2018.09.010. Epub 2018 Sep 7.
Most dyslipidemic conditions have been linked to an increased risk of cardiovascular disease. Over the past few years major advances have been made regarding the genetic and metabolic basis of dyslipidemias. Detailed characterization of the genetic basis of familial lipid disorders and knowledge concerning the effects of environmental factors on the expression of dyslipidemias have increased substantially, contributing to a better diagnosis in individual patients. In addition to these developments, therapeutic options to lower cholesterol levels in clinical practice have expanded even further in patients with familial hypercholesterolemia and in subjects with cardiovascular disease. Finally, promising upcoming therapeutic lipid lowering strategies will be reviewed. All these advances will be discussed in relation to current clinical practice with special focus on common lipid disorders including familial dyslipidemias.
大多数血脂异常与心血管疾病风险增加有关。在过去的几年中，血脂异常的遗传和代谢基础方面取得了重大进展。家族性脂质紊乱的遗传基础的详细特征以及环境因素对血脂异常表达的影响的知识有了实质性的增加，这有助于对个体患者进行更好的诊断。除了这些进展之外，在家族性高胆固醇血症患者和心血管疾病患者中，降低胆固醇水平的治疗选择在临床实践中进一步扩大。最后，将对有前途的即将出现的治疗性降脂策略进行综述。所有这些进展都将与当前的临床实践进行讨论，特别关注包括家族性血脂异常在内的常见血脂紊乱。
